替格瑞洛用于经皮冠状动脉介入治疗术后患者抗血小板治疗短期内的有效性和安全性研究

被引：51

作者：

马颖艳

王艳霞

徐白鸽

李娜

黄光华

王彩莲

方毅

韩雅玲

机构：

[1] 沈阳军区总医院心血管病研究所,心血管内科

来源：

中国介入心脏病学杂志 | 2014年 / 22卷 / 06期

关键词：

支架术; 经皮冠状动脉介入治疗; 替格瑞洛;

D O I：

暂无

中图分类号：

R541.4 [冠状动脉（粥样）硬化性心脏病（冠心病）];

学科分类号：

1002 ; 100201 ;

摘要：

目的观察替格瑞洛用于经皮冠状动脉介入治疗(PCI)患者抗血小板治疗的有效性和安全性。方法选择50例冠心病PCI术后应用氯吡格雷抗血小板,因血小板聚集率不达标且CYP2C19基因异常而改用替格瑞洛的患者。所有入选患者应用阿司匹林首次负荷剂量300 mg,维持剂量100 mg,每日一次;替格瑞洛维持剂量90 mg,每日二次,持续1年。研究主要终点为随访1个月的主要不良心血管事件(包括死亡、支架内血栓形成、支架内再狭窄、非致死性心肌梗死、靶血管血运重建)和脑卒中的发生率;次要终点为一般不良事件(包括轻微出血、过敏、呼吸困难)的发生率及血小板计数的变化情况。结果患者应用替格瑞洛后随访1个月未出现主要不良心血管事件和脑卒中;一般不良事件的发生率较低,2例(4%)出现呼吸困难,2例(4%)发生轻微出血,其中1例鼻出血,1例皮下淤血。应用替格瑞洛后血小板聚集率明显低于氯吡格雷,血小板计数未明显下降。结论替格瑞洛用于存在氯吡格雷抵抗的PCI患者抗血小板治疗,短期内安全有效。

引用

页码：380 / 383

页数：4

共 8 条

[1] 替格瑞洛治疗41例急性冠状动脉综合征患者的临床疗效 [J].

朱永宏 ;

贾国良 ;

周妙 ;

朱遵平 ;

袁战军 ;

周小欧 ;

张新文 ;

夏天 .

中国介入心脏病学杂志, 2013, 21 (06) :374-376

[2] 抗血小板药物研制与临床应用进展 [J].

阮长耿 .

中国药房, 2013, 24 (38) :3553-3555

[3]

2012 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction (Updating the 2007 Guideline and Replacing the 2011 Focused Update): A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines[J] . Hani Jneid,Jeffrey L. Anderson,R. Scott Wright,Cynthia D. Adams,Charles R. Bridges,Donald E. Casey,Steven M. Ettinger,Francis M. Fesmire,Theodore G. Ganiats,A. Michael Li

[4]

First Analysis of the Relation Between CYP2C19 Genotype and Pharmacodynamics in Patients Treated With Ticagrelor Versus Clopidogrel: The ONSET/OFFSET and RESPOND Genotype Studies[J] . Udaya S. Tantry,Kevin P. Bliden,Cheryl Wei,Robert F. Storey,Martin Armstrong,Kathleen Butler,Paul A. Gurbel.Circulation: Cardiovascular Genetics . 2010 (6)

[5]

Ticagrelor: An investigational oral antiplatelet treatment for reduction of major adverse cardiac events in patients with acute coronary syndrome[J] . Eugenia Nikolsky.Vascular Health and Risk Management . 2010 (defa)

[6]

Response to Ticagrelor in Clopidogrel Nonresponders and Responders and Effect of Switching Therapies: The RESPOND Study[J] . Paul A. Gurbel,Kevin P. Bliden,Kathleen Butler,Mark J. Antonino,Cheryl Wei,Renli Teng,Lars Rasmussen,Robert F. Storey,Tonny Nielsen,John W. Eikelboom,Georges Sabe-Affaki,Steen Husted,Dean J. Kereiakes,David Henderson,Dharmendra V. Patel,Udaya S. Tantry.Circulation . 2010 (10)

[7]

Randomized Double-Blind Assessment of the ONSET and OFFSET of the Antiplatelet Effects of Ticagrelor Versus Clopidogrel in Patients With Stable Coronary Artery Disease: The ONSET/OFFSET Study[J] . Paul A. Gurbel,Kevin P. Bliden,Kathleen Butler,Udaya S. Tantry,Tania Gesheff,Cheryl Wei,Renli Teng,Mark J. Antonino,Shankar B. Patil,Arun Karunakaran,Dean J. Kereiakes,Cordel Parris,Drew Purdy,Vance Wilson,Gary S. Ledley,Robert F. Storey.Circulation . 2009 (25)

[8]

Comparison of ticagrelor, the first reversible oral P2Y 12 receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial[J] . American Heart Journal . 2009 (4)

← 1 →